Research & Development

Collaborative initiative will evaluate an innovative RNA-based strategy to restore gene expression and accelerate therapeutic development for MED13L Syndrome and other rare neurodevelopmental disorders. CHICAGO, IL – August 5, 2026 – The MED13L Foundation today announced its participation in a collaborative research initiative led by COMBINEDBrain and Johns Hopkins University (JHU) to evaluate a novel RNA-based…

As featured in Brain & Life Magazine BOSTON, May 5, 2025 — The MED13L Foundation today announced a nearly $250,000 grant to help launch an innovative natural history study at Boston Children’s Hospital’s Rosamund Stone Zander Translational Neuroscience Center (RSZ TNC). The MED13L Syndrome Investigation of Natural History and Development (MIND Study) is a three-year…

One step closer to a therapeutic treatment. Could it be this easy? We Have a Hit! Rarebase Delivers. It’s not a home run, but a solid double from Rarebase! After a long couple of years and two rounds of testing, naproxen was shown to upregulate MED13L mRNA in MED13L patient-derived neurons